Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies

Lilly Research Laboratories, Eli Lilly, Indianapolis, Indiana, United States
Journal of Pharmaceutical and Biomedical Analysis (Impact Factor: 2.98). 10/2005; 39(3-4):685-90. DOI: 10.1016/j.jpba.2005.03.037
Source: PubMed


The double antigen bridging immunoassay has been used extensively for detection of immunogenicity responses to therapeutic monoclonal antibodies. We have analyzed parameters affecting performance of this type of immunoassay including microtiter plate antigen coating concentration, enzyme-labeled antigen conjugate dilution and assay format (one-step versus two-step). We present results demonstrating that the format of the assay has a significant impact on the optimal parameters to maximize assay performance. A one-step assay format achieves maximal sensitivity across a broad range of coating concentrations and at a lower concentration of conjugate than that in a two-step format. In contrast, a two-step format requires very low coating concentrations and higher conjugate concentrations to achieve maximal sensitivity and suffers from significantly reduced sensitivity at higher coating concentrations. Together, these findings indicate that a one-step assay format can greatly reduce the effect of coating concentration variation on assay performance.

1 Follower
9 Reads
  • Source
    • "Different assay formats have a significant impact on the optimal parameters used to maximize assay performance [13]. Anti-GAD and anti-IA-2 bridging ELISA tests have recently been developed that have outperformed classic liquid-phase RIA formats [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes (T1D) is an autoimmune disease which results from the destruction of pancreatic beta cells. Autoantibodies directed against islet antigens are valuable diagnostic tools. Insulin autoantibodies (IAAs) are usually the first to appear and also the most difficult to detect amongst the four major islet autoantibodies. A non-radioactive IAA bridging ELISA was developed to this end. In this assay, one site of the IAAs from serum samples is bound to a hapten-labeled insulin (GC300-insulin), which is subsequently captured on anti-GC300 antibody-coated 96-well plates. The other site of the IAAs is bound to biotinylated insulin, allowing the complex to be detected by an enzyme-streptavidin conjugate. In the present study, 50 serum samples from patients with newly diagnosed T1D and 100 control sera from non-diabetic individuals were analyzed with our new assay and the results were correlated with an IAA radioimmunoassay (RIA). Using IAA bridging ELISA, IAAs were detected in 32 out of 50 T1D children, whereas with IAA RIA, 41 out of 50 children with newly diagnosed T1D were scored as positive. In conclusion, the IAA bridging ELISA could serve as an attractive approach for rapid and automated detection of IAAs in T1D patients for diagnostic purposes.
    PLoS ONE 07/2013; 8(7):e69021. DOI:10.1371/journal.pone.0069021 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Monoclonal antibody therapeutics typically have relatively long half-lives and can be dosed at high levels. Although formation of anti-drug antibodies (ADA) is relatively rare, detection of these antibodies can be very difficult in the presence of high circulating levels of drug. Typically these ADA are detected by bridging ELISAs which can be very sensitive to even low levels of drug. We describe an ELISA method based on affinity capture of ADA on solid-phase drug followed by removal of excess free drug, release and transfer of bound ADA and subsequent detection using biotinylated drug. The assay is both sensitive and highly tolerant to free drug with detection of 500 ng/ml of ADA readily achieved in the presence of 500 mug/ml of drug.
    Journal of Immunological Methods 11/2007; 327(1-2):10-7. DOI:10.1016/j.jim.2007.07.004 · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic monoclonal antibodies (MoAb) have become important tools in the treatment of numerous diseases. Many of these MoAb are present in the blood at very high levels due to high dosing and long half-lives. Quantification of biomarkers bound by these therapeutic MoAb can be an important factor in determining efficacy and dosing requirements. However, quantitation of these biomarkers with reasonable accuracy can be very difficult to accomplish due to concomitant binding of the therapeutic MoAb. We describe here a novel method for quantifying total (free plus bound) biomarker concentration in the presence of high levels of therapeutic MoAb using a single non-competing MoAb in a capture/elution format. This assay has the capability to accurately detect and quantitate circulating ng/ml biomarker levels in the presence of 200 microg/ml or more of therapeutic MoAb.
    Journal of Pharmaceutical and Biomedical Analysis 08/2008; 48(3):897-901. DOI:10.1016/j.jpba.2008.07.012 · 2.98 Impact Factor
Show more